Holen Sie sich die Stockscreener-App
15.22
3.19%
0.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.75
Offen:
$14.9
24-Stunden-Volumen:
3.91M
Relative Volume:
1.06
Marktkapitalisierung:
$1.50B
Einnahmen:
$669.43M
Nettoeinkommen (Verlust:
$-609.36M
KGV:
-2.4926
EPS:
-6.1061
Netto-Cashflow:
$-507.20M
1W Leistung:
+4.97%
1M Leistung:
-42.63%
6M Leistung:
-32.20%
1J Leistung:
-50.74%
1-Tages-Spanne:
$14.67
$15.28
1-Wochen-Bereich:
$14.11
$15.53
52-Wochen-Spanne:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
15.22 | 1.43B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.8%Time to Buy? - MarketBeat
Return on invested capital % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat - biospace.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts - MarketBeat
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results - Stocktwits
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy - Stocktwits
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Ultragenyx Stock Jumps on Landmark FDA Approval - Barron's
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - ca.finance.yahoo.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz - biospace.com
Treatment invented at Nationwide Children’s for deadly disease gets FDA approval - The Business Journals
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - Yahoo Finance
Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
RARE Maintained by Evercore ISI Group -- Price Target Raised to $18 - GuruFocus
Is Ultragenyx Stock a Buy With 2 FDA Vouchers Worth a Quarter of Its Market Value? - Investing.com
RARE Maintained by Barclays -- Price Target Raised to $35.00 - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Andelyn Biosciences reaches commercial gene therapy manufacturing milestone with Fayuvi - Manufacturing Chemist
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now? - Kalkine Media
Ultragenyx wins first-ever FDA approval in Sanfilippo syndrome type A - The Pharma Letter
Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets - ad-hoc-news.de
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending - webull.com
FDA approves new gene therapy as first treatment for Sanfilippo A - Sanfilippo Syndrome News
Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo - MedCity News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out - ACCESS Newswire
RARE - Finviz
Ultragenyx's $3.95 Million Fayuvi Secures First-Ever FDA Approval for Sanfilippo Syndrome Type A - finance.biggo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A - BioPharm International
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy - theglobeandmail.com
Ultragenyx Turns To Launch Execution After Long Road For Sanfilippo Gene Therapy - insights.citeline.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00 - MarketBeat
Ultragenyx sets $3.95 million price for rare disease gene therapy - CNBC
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A - Pharmaceutical Executive
Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A - AllSci
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest - Benzinga
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVI™ to Treat Sanfilippo Syndrome Type A (MPS IIIA) - PR Newswire
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):